¹⁷⁷Lu-DOTATATE and ¹⁷⁷Lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatment

Abstract

Patients with radioiodine-refractory differentiated thyroid cancer (RrDTC) have only a limited or no benefit from radioiodine therapy. For these patients, tyrosine kinase inhibitors have demonstrated encouraging results in advanced RrDTC. Nevertheless, these therapies are related with substantial side effects and a high cost. Somatostatin receptor-based therapies have shown promising findings in advanced RrDTC. Recently, prostate-specific membrane antigen (PSMA) expression was seen in advanced RrDTC in imaging studies. This study presents a case of RrDTC who was treated with ¹⁷⁷Lu-DOTATATE and ¹⁷⁷Lu-PSMA, presumably as a first report in this regard.

Keywords

¹⁷⁷Lu - DOTATATE - prostate-specific membrane antigen - radioiodine-refractory differentiated thyroid cancer

Introduction

Patients with radioiodine-refractory differentiated thyroid cancer (RrDTC) have only a limited or no benefit from radioiodine therapy so that they need other treatment strategies such as surgery and/or external irradiation to provide a systemic approach to prevent metastatic tumor spread. Tyrosine kinase inhibitors have demonstrated encouraging results in advanced RrDTC but is associated with substantial side effects and a high cost. Somatostatin receptor (SSTR)-based therapies have shown promising findings in advanced RrDTC.[1],[2] Recently, prostate-specific membrane antigen (PSMA) expression was seen in advanced RrDTC in imaging studies.[3]

This study presents a case of RrDTC who was treated with177 Lu-DOTATATE and177 Lu-PSMA, and is presumably the first report in this regard.

Case Report

The patient was a 42-year-old man who had a progressive disease with neck and lung metastases and was treated with 25.9 GBq (700 mCi)131 I and also sorafenib for 6 months. The patient had progressive dyspnea due to massive pleural effusions and also repeated surgical intervention in thorax [Figure 1a]. The last radioiodine therapy with 7.4 GBq was given after a long period sorafenib treatment, which was associated with the patient experiencing severe side effects. The posttreatment whole-body imaging showed a faint uptake in the involved neck and lung regions [Figure 1b]. Few months later he underwent octreotide scintigraphy which depicted faint uptake in the neck and lung [Figure 1c], and he immediately received 7.4 GBq177 Lu-DOATATE, and also posttherapy whole-body imaging which demonstrated some uptake in the neck and lung [Figure 1d]. The patient showed continued disease progression and severe dyspnea which required repeated hospitalization. Based on the promising findings of ⁶⁸Ga-PSMA,[3],[4] Our multidisciplinary team proposed PSMA scanning which showed more uptake than octreotide scan in the involved regions [Figure 1e] and [Figure 1f]. He then received 7.4GBq177 Lu-PSMA, and once more the posttherapy whole-body imaging revealed more uptake than posttherapy whole-body imaging following177 Lu-DOTATE [Figure 1g]. The patient died 2 weeks posttherapy unexpectedly due to cardiac arrest. It should be mentioned that the number of hospitalization after PRRT were fewer than before. Also, an interesting clinical point was that the respiratory function improved in the early days after therapy, so that although he could not walk alone before PRRT, he was able to walk alone for hours in the early days after PRRT.

Figure 1 The different imaging modalities in a 42-year-old man with a radioiodine-refractory differentiated thyroid cancer. Computed tomography scan of thorax (a); post ¹³¹I ablation whole-body scan (b); ^99mTc octreotide scintigraphy (c); post ¹⁷⁷Lu-DOTATATE whole-body imaging (d); 2 and 24 h prostate-specific membrane antigen scintigraphy (e and f) and post ¹⁷⁷Lu-prostate-specific membrane antigen whole-body imaging (g)

Discussion

In this study, we present both177 Lu-DOTATATE and177 Lu-PSMA therapies in a patient with RrDTC.

Recently, Roll et al. presented findings of five RrDTC patients with limited further therapeutic options and documented expression of SSRT using ⁶⁸Ga-DOTATATE-PET/CT received 2–4 cycles of PRRT with177 Lu-DOTATATE. They demonstrated that only one out of five patients depicted a partial response, whereas three patients had a progressive disease. One patient had discordant findings between stable imaging results albeit rising Tg levels.[2]

Overall, recent studies demonstrate heterogeneous results ranging from progressive disease under PRRT to favorable results with disease control in up to 60% of patients.[1],[5],[6] To the best of our knowledge, the literature is scarce regarding177 Lu-PSMA therapy in the patients with RrDTC, so further studies are needed to evaluate this subgroup of DTC.

Such cases illustrate the potential complexity, and interdisciplinary strategies that may end in managing dilemmas. It appears that there is a need for a multidisciplinary pragmatic approach for a change in the management of patients with RrDTC.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Conflict of Interest

There are no conflicts of interest.

Financial support and sponsorship

Nil.

• References

• 1 Salavati A, Puranik A, Kulkarni HR, Budiawan H, Baum RP. Peptide receptor radionuclide therapy (PRRT) of medullary and nonmedullary thyroid cancer using radiolabeled somatostatin analogues. Semin Nucl Med 2016;46:215-24.
• 2 Roll W, Riemann B, Schäfers M, Stegger L, Vrachimis A 177Lu-DOTATATE therapy in radioiodine-refractory differentiated thyroid cancer: A Single center experience. Clin Nucl Med 2018;43:e346-51.
• 3 Taywade SK, Damle NA, Bal C. PSMA expression in papillary thyroid carcinoma: Opening a new horizon in management of thyroid cancer? Clin Nucl Med 2016;41:e263-5.
• 4 Sager S, Vatankulu B, Uslu L, Sönmezoglu K. Incidental detection of follicular thyroid carcinoma in 68Ga-PSMA PET/CT imaging. J Nucl Med Technol 2016;44:199-200.
• 5 Budiawan H, Salavati A, Kulkarni HR, Baum RP. Peptide receptor radionuclide therapy of treatment-refractory metastatic thyroid cancer using(90) Yttrium and (177)Lutetium labeled somatostatin analogs: Toxicity, response and survival analysis. Am J Nucl Med Mol Imaging 2013;4:39-52.
• 6 Versari A, Sollini M, Frasoldati A, Fraternali A, Filice A, Froio A, et al. Differentiated thyroid cancer: A new perspective with radiolabeled somatostatin analogues for imaging and treatment of patients. Thyroid 2014;24:715-26.

Publication History

Received: 11 December 2018

Accepted: 21 December 2018

Article published online:
22 April 2022